[{"orgOrder":0,"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follicum Re-Starts phase II Study With FOL-005 for Stimulation of Hair Growth and Expands the Number of Study Centres","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All patients included in Follicum\u2019s Phase II Study with FOL-005 for Stimulation of Hair Growth","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follicum AB Reports that All Patients Have Completed Treatment With FOL-005 in the Phase II Study Against Hair Loss","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Follicum AB
FOL-005 is a modified, short version of the endogenous protein, osteopontin. The ongoing double-blind and placebo-controlled Phase IIa study examines the safety and efficacy of FOL-005 in a new, cream-like formulation.
The ongoing double-blind and placebo-controlled Phase II study examines the safety and efficacy of FOL-005 in a new, cream-like formulation. Patients themselves apply one of three different strengths of FOL-005 or placebo to the scalp once a day.
In two previous clinical studies, FOL-005 administered as an intradermal injection has been shown to be an effective and safe treatment for stimulation of hair growth.